Involvement of endogenous ouabain-like compound in the cardiac hypertrophic process in vivo

Life Sciences

Volumn 80, Issue 14, 2007, Pages 1303-1310

  Skoumal, Réka ^a   Szokodi, István ^b   Aro, Jani ^c   Földes, Gábor ^a   Göoz, Mónika ^d   Seres, Leila ^e   Sármán, Balázs ^a   Lakó Futó, Zoltán ^a   Papp, Lajos ^b   Vuolteenaho, Olli ^c   Leppäluoto, Juhani ^c   deChâtel, Rudolf ^a   Ruskoaho, Heikki ^c   Tóth, Miklós ^a,e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF OULU   (Finland)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e National Institute of Cardiology Budapest   (Hungary)

Author keywords

Angiotensin II; Atrial natriuretic peptide; Hypertrophy; Norepinephrine; Ouabain

Indexed keywords

ANGIOTENSIN II; NORADRENALIN; OUABAIN;

ADRENALECTOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART HYPERTROPHY; HEART MUSCLE CELL; MALE; NONHUMAN; OSMOTIC MINIPUMP; RAT;

ADRENALECTOMY; ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOTTING, NORTHERN; CARDENOLIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCYTES, CARDIAC; NOREPINEPHRINE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SAPONINS; UP-REGULATION; VASOCONSTRICTOR AGENTS;

RATTUS; STROPHANTHUS GRATUS;

EID: 33847262462     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.12.026     Document Type: Article

References (57)

1. Abdelrahman A.M., Harmsen E., and Leenen F.H. Dietary sodium and Na, K-ATPase activity in Dahl salt-sensitive versus salt-resistant rats. Journal of Hypertension 13 (1995) 517-522
2. Akers W.S., Cross A., Speth R., Dwoskin L.P., and Cassis L.A. Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy. American Journal of Physiology. Heart and Circulatory Physiology 279 (2000) H2797-H2806
3. +-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 31 (1998) 1097-1103
4. Balzan S., Neglia D., Ghione S., D'Urso G., Baldacchino M.C., Montali U., and L'Abbate A. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. European Journal of Heart Failure 3 (2001) 165-171
5. Barki-Harrington L., Perrino C., and Rockman H. Network integration of the adrenergic system in cardiac hypertrophy. Cardiovascular Research 63 (2004) 391-402
6. Bauer N., Muller-Ehmsen J., Kramer U., Hambarchian N., Zobel C., Schwinger R.H., Neu H., Kirch U., Grunbaum E.G., and Schoner W. Ouabain-like compound changes rapidly on physical exercise in humans and dogs: effects of beta-blockade and angiotensin-converting enzyme inhibition. Hypertension 45 (2005) 1024-1028
7. Beck M., Szalay K.S., Nagy G.M., Toth M., and de Chatel R. Production of ouabain by rat adrenocortical cells. Endocrine Research 22 (1996) 845-849
8. Beznak M. The effect of the adrenals and the pituitary on blood pressure and cardiac hypertrophy of rats. The Journal of Physiology 116 (1952) 219-227
9. Butt A.N., Semra Y.K., Ho C.S., and Swaminathan R. Effect of high salt intake on plasma and tissue concentration of endogenous ouabain-like substance in the rat. Life Sciences 61 (1997) 2367-2373
10. Calderone A., Takahashi N., Izzo Jr. N.J., Thaik C.M., and Colucci W.S. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation 92 (1995) 2385-2390
11. Caron K.M., James L.R., Kim H.S., Knowles J., Uhlir R., Mao L., Hagaman J.R., Cascio W., Rockman H., and Smithies O. Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 3106-3111
12. Chirgwin J.M., Przybyla A.E., MacDonald R.J., and Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18 (1979) 5294-5299
13. Dostal D.E., and Baker K.M. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?. Circulation Research 85 (1999) 643-650
14. Dostanic I., Lorenz J.N., Schultz J.J., Grupp I.L., Neumann J.C., Wani M.A., and Lingrel J.B. The alpha2 isoform of Na, K-ATPase mediates ouabain-induced cardiac inotropy in mice. Journal of Biological Chemistry 278 (2003) 53026-53034
15. Dostanic I., Paul R.J., Lorenz J.N., Theriault S., Van Huysse J.W., and Lingrel J.B. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. American Journal of Physiology. Heart and Circulatory Physiology 288 (2005) H477-H485
16. Dostanic-Larson I., Van Huysse J.W., Lorenz J.N., and Lingrel J.B. The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 15845-15850
17. +-ATPase and biological significance of their cardiac glycoside binding site. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 290 (2006) R524-R528
18. D'Urso G., Frascarelli S., Balzan S., Zucchi R., and Montali U. Production of ouabain-like factor in normal and ischemic rat heart. Journal of Cardiovascular Pharmacology 43 (2004) 657-662
19. Feldman A.M., Weinberg E.O., Ray P.E., and Lorell B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circulation Research 73 (1993) 184-192
20. Ferrandi M., Manunta P., Balzan S., Hamlyn J.M., Bianchi G., and Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 30 (1997) 886-896
21. Ferrandi M., Molinari I., Barassi P., Minotti E., Bianchi G., and Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. Journal of Biological Chemistry 279 (2004) 33306-33314
22. Flynn T.G., Davies P.L., Kennedy B.P., de Bold M.L., and de Bold A.J. Alignment of rat cardionatrin sequences with the preprocardionatrin sequence from complementary DNA. Science 228 (1985) 323-325
23. Foldes G., Suo M., Szokodi I., Lako-Futo Z., deChatel R., Vuolteenaho O., Huttunen P., Ruskoaho H., and Toth M. Factors derived from adrenals are required for activation of cardiac gene expression in angiotensin II-induced hypertension. Endocrinology 142 (2001) 4256-4263
24. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annual Review of Physiology 65 (2003) 45-79
25. Gottlieb S.S., Rogowski A.C., Weinberg M., Krichten C.M., Hamilton B.P., and Hamlyn J.M. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86 (1992) 420-425
26. +)ATPase associated with essential hypertension. Nature 300 (1982) 650-652
27. Hamlyn J.M., Blaustein M.P., Bova S., DuCharme D.W., Harris D.W., Mandel F., Mathews W.R., and Ludens J.H. Identification and characterization of an ouabain-like compound from human plasma. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 6259-6263
28. Holtwick R., van Eickels M., Skryabin B.V., Baba H.A., Bubikat A., Begrow F., Schneider M.D., Garbers D.L., and Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. Journal of Clinical Investigation 111 (2003) 1399-1407
29. Huang L., Li H., and Xie Z. Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression of several late response genes. Journal of Molecular and Cellular Cardiology 29 (1997) 429-437
30. James P.F., Grupp I.L., Grupp G., Woo A.L., Askew G.R., Croyle M.L., Walsh R.A., and Lingrel J.B. Identification of a specific role for the Na, K-ATPase alpha 2 isoform as a regulator of calcium in the heart. Molecular Cell 3 (1999) 555-563
31. Kaddoura S., Firth J.D., Boheler K.R., Sugden P.H., and Poole-Wilson P.A. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 93 (1996) 2068-2079
32. Laks M.M., Morady F., and Swan H.J. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64 (1973) 75-78
33. Laredo J., Shah J.R., Lu Z.R., Hamilton B.P., and Hamlyn J.M. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension 29 (1997) 401-407
34. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine 322 (1990) 1561-1566
35. 2+ concentrations. Journal of Biological Chemistry 275 (2000) 27838-27844
36. Lorell B.H., and Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102 (2000) 470-479
37. Ludens J.H., Clark M.A., DuCharme D.W., Harris D.W., Lutzke B.S., Mandel F., Mathews W.R., Sutter D.M., and Hamlyn J.M. Purification of an endogenous digitalis like factor from human plasma for structural analysis. Hypertension 17 (1991) 923-929
38. Ludens J.H., Clark M.A., Robinson F.G., and DuCharme D.W. Rat adrenal cortex is a source of a circulating ouabain like compound. Hypertension 19 (1992) 721-724
39. Luodonpaa M., Leskinen H., Ilves M., Vuolteenaho O., and Ruskoaho H. Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 286 (2004) R1085-R1092
40. Majalahti-Palviainen T., Hirvinen M., Tervonen V., Ilves M., Ruskoaho H., and Vuolteenaho O. Gene structure of a new cardiac peptide hormone: a model for heart-specific gene expression. Endocrinology 141 (2000) 731-740
41. Manunta P., Rogowski A.C., Hamilton B.P., and Hamlyn J.M. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. Journal of Hypertension 12 (1994) 549-560
42. Manunta P., Stella P., Rivera R., Ciurlino D., Cusi D., Ferrandi M., Hamlyn J.M., and Bianchi G. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 34 (1999) 450-456
43. Matsubara H., Yamamoto J., Hirata Y., Mori Y., Oikawa S., and Inada M. Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats. Circulation Research 66 (1990) 176-184
44. Mercadier J.J., Samuel J.L., Michel J.B., Zongazo M.A., de la Bastie D., Lompre A.M., Wisnewsky C., Rappaport L., Levy B., and Schwartz K. Atrial natriuretic factor gene expression in rat ventricle during experimental hypertension. American Journal of Physiology 257 (1989) H979-H987
45. Molkentin J.D., and Dorn II G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annual Review of Physiology 63 (2001) 391-426
46. Nichols J.R., Clancy R.L., and Gonzalez N.C. Role of adrenals on development of pressure-induced myocardial hypertrophy. American Journal of Physiology 244 (1983) H234-H238
47. Rapacciuolo A., Esposito G., Caron K., Mao L., Thomas S.A., and Rockman H.A. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. Journal of the American College of Cardiology 38 (2001) 876-882
48. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacological Reviews 44 (1992) 479-602
49. Sadoshima J., Xu Y., Slayter H.S., and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 (1993) 977-984
50. Schoner W. Ouabain, a new steroid hormone of adrenal gland and hypothalamus. Experimental and Clinical Endocrinology & Diabetes 108 (2000) 449-454
51. Schwinger R.H., Bundgaard H., Muller-Ehmsen J., and Kjeldsen K. The Na, K-ATPase in the failing human heart. Cardiovascular Research 57 (2003) 913-920
52. Tokola H., Salo K., Vuolteenaho O., and Ruskoaho H. Basal and acidic fibroblast growth factor-induced atrial natriuretic peptide gene expression and secretion is inhibited by staurosporine. European Journal of Pharmacology 267 (1994) 195-206
53. Vakkuri O., Arnason S.S., Joensuu P., Jalonen J., Vuolteenaho O., and Leppaluoto J. Radioiodinated tyrosyl-ouabain and measurement of a circulating ouabain-like compound. Clinical Chemistry 47 (2001) 95-101
54. Vikstrom K.L., Bohlmeyer T., Factor S.M., and Leinwand L.A. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circulation Research 82 (1998) 773-778
55. Womble J.R., Larson D.F., Copeland J.G., Brown B.R., Haddox M.K., and Russell D.H. Adrenal medulla denervation prevents stress-induced epinephrine plasma elevation and cardiac hypertrophy. Life Sciences 27 (1980) 2417-2420
56. Yamada H., Naruse M., Naruse K., Demura H., Takahashi H., Yoshimura M., and Ochi J. Histological study on ouabain immunoreactivities in the mammalian hypothalamus. Neuroscience Letters 141 (1992) 143-146
57. Yamazaki T., Komuro I., Zou Y., Kudoh S., Shiojima I., Hiroi Y., Mizuno T., Aikawa R., Takano H., and Yazaki Y. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. Circulation 95 (1997) 1260-1268